Trial reportBMC infectious diseases2026
Baseline determinants of adherence for drug-sensitive TB treatment in a South African prospective cohort: a focus on HIV infection and anti-retroviral therapy, clinical care access, and TB stigma.
Trial report in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundInadequate adherence to tuberculosis (TB) treatment increases the risk of treatment failure and recurrence. Identifying factors contributing to poor adherence could refine targeting strategies and optimize resource distribution. We examined specific individual-level factors for TB treatment adherence among adults with drug-sensitive TB, including HIV status, antiretroviral therapy, time to access clinical care, and perceived stigma.
methodsData are from the “TB Mate” cluster-randomized trial, which evaluated a TB treatment adherence intervention across 18 public health clinics in South Africa (PACTR201902681157721). Treatment adherence was measured using smart pillboxes, with pillbox opening recorded as a proxy for the dose taken. Adults in the control group, utilizing the pillbox in silent mode, were included in this analysis. We used logistic regression to model poor adherence (< 80% pillbox engagement), and negative binomial regression to model adherence as a count of pillbox engagement. Directed acyclic graphs informed confounder selection in the models.
resultsAmong 1,213 participants (nine clinics) in the control group, 61.2% (742) were male, the median age was 36 years, 63% (769) were living with HIV, with 66% (507/769) on antiretroviral therapy. The median time to access clinical care was 127 min and 95% (1151/1213) reported no perceived stigmatization upon starting TB treatment. Overall 51% (614) exhibited adherence below 80%, with a geometric mean pillbox engagement of 59.6%. Living with HIV was associated with poor adherence to TB treatment, with an adjusted odds ratio of 1.68 (95% confidence interval [CI] 1.27–2.22) for < 80% adherence and an adjusted rate ratio of 0.90 (0.83–0.97) for pillbox engagement, compared to being HIV-negative. Antiretroviral therapy, time to clinical care access, and perceived stigma showed no association with either measure of adherence.
conclusionsThe low adherence underscores the necessity for TB treatment support interventions, particularly among those living with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.